



September 13, 2019

Zimmer GmbH
Tiana Steinhoff
Regulatory Affairs Specialist
Sulzerallee 8
Winterthur, 8404 CH

Re: K192217

Trade/Device Name: NCB Plating System Distal Femur and Proximal Tibia
Regulation Number: 21 CFR 888.3030
Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances And Accessories
Regulatory Class: Class II
Product Code: HRS, HWC
Dated: August 12, 2019
Received: August 15, 2019

Dear Tiana Steinhoff:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Shumaya Ali, MPH
Assistant Director
DHT6C: Division of Restorative, Repair
and Trauma Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K192217

Device Name

NCB® Plating System, Distal Femur and Proximal Tibia

Indications for Use (Describe)

The NCB Plating System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



510(K) SUMMARY

510(k) SUMMARY

Sponsor:	Zimmer GmbH Sulzerallee 8, P.O. Box 8404 Winterthur, Switzerland
Contact Person:	Tiana Steinhoff Specialist, Regulatory Affairs Telephone: +41 58 854 82 96 Fax: +41 52 244 86 58
Date:	August 12 th , 2019
Trade Name:	NCB® Plating System, Distal Femur and its line extension Proximal Tibia
Classification Product Code :	Plate System HRS HWC
Device Classification Name:	Plate, fixation, bone Screw, fixation, bone
Regulation Number / Description:	21 CFR § 888.3030 Single/multiple component metallic bone fixation appliances and accessories 21 CFR § 888.3040 Smooth or threaded metallic bone fixation fastener
Predicate Device:	NCB® Plating System, Distal Femur, manufactured by Zimmer GmbH, K042695, cleared in October 2004 (primary predicate) NCB® Plating System, Proximal Tibia, manufactured by Zimmer GmbH, K061211, cleared in June 2006 (line extension of K042695)
Device Description:	The NCB Plating System is an extramedullary internal fixation plate system to be used for either distal femoral or proximal tibia fractures. It is intended to be implanted either percutaneously or by a traditional open method.
Intended Use:	The NCB Plating System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones.
Comparison to Predicate Device:	The intended use of the modified devices, as described in its labeling, has not changed as a result of the modifications



510(K) SUMMARY

	proposed in the present submission. The proposed packaging configuration and the methods to support the package integrity have been previously cleared for Zimmer GmbH products. Zimmer GmbH is furthermore seeking clearance for certain system-specific Class II instruments - these instruments that have previously considered Class I exempt and correction of classification to Class II is proposed within present submission.
Performance Data (Nonclinical and/or Clinical):	<i>Non-Clinical Performance and Conclusions:</i> Class II: Amendment of Design Controls with verification of mechanical integrity and resistance. <i>Clinical Performance and Conclusions:</i> Clinical data and conclusions were not needed for this device.
Conclusion:	The subject devices have the same intended use and same indications for use as the predicate devices. The subject devices use the same operating principle, incorporate the same basic design and labeling and are manufactured and sterilized using the same materials and processes as the predicate devices. Except for the modifications described in this submission the subject devices are identical to the predicate devices, and the performance data and analyses demonstrate that: • any differences do not raise new questions of safety and effectiveness as established with performance testing; and • the subject devices are at least as safe and effective as the legally marketed predicate devices.